Infectech, Inc.

Marv Enterprises, LLC

Nanologix, Inc.

Halberd Corporation

Altman Enterprises, LLC

Mitchell S Felder

Robert-A Ollar

Robert A Ollar

Robert- A Ollar

Harry R Diz

Thomas A Kelly

Justin Felder

Robert -a Ollar

Disclosed is a method for treating of Cockayne Syndrome (CS). Specifically, the invention pertains to a method for the extracorporeal treatment of a body fluid by removing the body fluid from a living body diseased with CS, and applying a targeted antibody either a mammalian target of rapamycin (mTOR) antigen or a death-associated protein 1 (DAP1) in a bodily fluid such as blood, creating an antibody-antigen complex, removing antibody-antigen complex from the bodily fluid, and returning the purified bodily fluid to the CS patient.

Treatment method for Cockayne syndrome

An article and method to treat extracorporeally a patient's bodily fluid. The bodily fluid can include blood, cerebral spinal fluid and lymph. A first stage of the method includes applying a treatment. The treatment can comprise dosing with a medication, thermal treatment, or irradiation. The treatment can occur at levels that could otherwise compromise the patient's health. A second stage of the method substantially removes the treatment from the bodily fluid. The bodily fluid can then be returned to the patient. The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment. The method can be a continuous process such as, for example, a dialysis process.

Sequential extracorporeal treatment of bodily fluids

A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain. Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases, such as MS. The treatment comprises about 1-10 mg naltrexone, at least about 20 &#x3bc;g vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg coenzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclcobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine, and combinations thereof. The treatment can be administered orally, and can decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.

Medication and treatment for disease

A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells. The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent. The method includes placing a patient's blood in apposition of the antineoplastic agent by pumping the blood through the stent. The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.

Utilization of stents for the treatment of blood borne carcinomas

The present invention provides a system of baiting and growing microorganisms on a gelatinous matrix. A bioreactor is provided wherein the bioreactor provides an environment conducive to the breakdown of organic aqueous material and the production of hydrogen from microorganisms and restrictive to the production of methane from methanogens. The bioreactor includes substrates coated with a gelatinous matrix, wherein the gelatinous matrix coating is replenished by additional coating material pumped into interior channels of the substrates wherein the substrates are permeable by the coating.

Production of hydrogen gas and isolation of hydrogen producing microorganisms using replenishing coated substrates

A method of inducing apoptosis in a cell. The method includes providing an impenetrable and nonmetabolizable material, such as paraffin or agar, and introducing the cell into a contacting relationship with the material. The method also includes providing a substrate and coating the substrate with the impenetrable and nonmetabolizable material.

Inducing apoptosis in a mammalian cell by contacting with paraffin or agar

A method of determining the presence or absence of a nonparaffinophilic microorganism in a specimen taken from a patient includes providing a receptacle containing an aqueous solution that does not contain a carbon source and inoculating the aqueous solution with the specimen. A slide having bound thereto a carbon source is placed into the receptacle. By analyzing the slide after exposure to the specimen, the presence or absence of a nonparaffinophilic microorganism in the specimen can be determined. An associated apparatus is also disclosed.

Method of determining the presence or absence of a nonparaffinophilic

A method of determining the presence or absence of a nonparaffinophilic microorganism in a specimen taken from a patient includes providing a receptacle containing an aqueous solution and inoculating the aqueous solution with the specimen. A slide coated with a carbon source is placed into the receptacle. By analyzing the slide after exposure to the specimen, the presence or absence of a nonparaffinophilic microorganism in the specimen can be determined. An associated apparatus is also disclosed.

Apparatus for determining the presence or absence of a

A method of determining the presence of a paraffinophilic microorganism in a specimen taken from a patient. The method includes providing a receptacle containing an aqueous solution and adjusting the solution to mimic the in vivo clinical conditions of the patient. The method then further includes inoculating the solution with the specimen and then placing in the receptacle a paraffin coated slide to bait the paraffinophilic microorganism. The slide is then analyzed after exposure to the specimen to determine the presence or absence of the paraffinophilic microorganism. An associated apparatus is also disclosed.

Apparatus for determining the presence or absence of a paraffinophilic

A method of determining the sensitivity of at least one paraffinophilic microorganism from a specimen obtained from a patient to different antimicrobial agents and predetermined quantities thereof includes providing at least one receptacle containing an aqueous solution and adjusting the solution to mimic the in vivo clinical conditions of the patient. The method then includes inoculating the solution with the specimen and then placing into the receptacle (i) a paraffin coated slide to bait the at least one paraffinophilic microorganism and (ii) a predetermined quantity of an antimicrobial agent to be tested. The slide is then observed for paraffinophilic microorganism growth or lack thereof to determine whether the predetermined quantity of the antimicrobial agent is effective in inhibiting growth of the paraffinophilic microorganisms on the slide. An associated apparatus is also provided.

Determining sensitivity of paraffinophilic microorganisms to

An apparatus for determining sensitivity of at least one paraffinophilic microorganism from a specimen obtained from a patient to different antimicrobial agents and predetermined quantities thereof. The apparatus includes a receptacle adapted to contain an aqueous solution, an amount of antimicrobial agent to be tested and the specimen. The aqueous solution is adjusted to mimic the in vivo clinical conditions of the patient. The apparatus further includes a paraffin coated slide adapted to being placed in the receptacle.

Method for determining the antimicrobial agent sensitivity of a

A method for determining the sensitivity of at least one nonparaffinophilic microorganism from a specimen obtained from a patient to an antimicrobial agent. The method includes providing at least one receptacle containing an aqueous solution that does not contain a carbon source and inoculating the solution with the specimen. The method further includes placing into the receptacle (i) a slide having bound thereto a carbon source and (ii) a predetermined quantity of an antimicrobial agent to be tested. By observing the nonparaffinophilic microorganism growth or lack thereof on the slide, it can be determined whether the predetermined quantity of the antimicrobial agent is effective in inhibiting growth of the nonparaffinophilic microorganism on the slide. An associated apparatus is also disclosed.

A method of automatically testing the sensitivity of a paraffinophilic microorganism to different antimicrobial agents and concentrations thereof includes a plurality of receptacles each containing an amount of liquid medium, an antimicrobial agent to be tested and the microorganism to be tested. A paraffin containing slide is placed in each receptacle after which incubation is effected. A light scatter sensor is employed to automatically and sequentially monitor the extent of microorganism growth on the slides and the growth on each slide is employed to determine which antimicrobial agent and which concentration is effective to resist growth of the paraffinophilic microorganism. The slides are moved sequentially in operative relationship with the light scatter sensor while resisting rotational movement of the slides. Positive and negative control slides are preferably employed as is a computer in receiving and processing the results of the slide testing. Related apparatus is disclosed.

Growing community of inventors

Hermitage, PA, United States of America

Mitchell S Felder